1. Home
  2. Clinical Topics
  3. FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome
Clinical TopicsDrugs and DevicesEndocrinologyWeb Exclusives

FDA approves Korlym for hyperglycemia in patients with endogenous Cushing’s syndrome

Share

On Feb. 17, the U.S. Food and Drug Administration (FDA) announced the approval of Korlym (mifepristone) to control hyperglycemia in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts